Last reviewed · How we verify
Taurolidine Urokinase
Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing.
Taurolidine urokinase works by combining the antimicrobial properties of taurolidine with the fibrinolytic properties of urokinase to treat infections and promote wound healing. Used for Treatment of catheter-related bloodstream infections.
At a glance
| Generic name | Taurolidine Urokinase |
|---|---|
| Also known as | Taurolock Urokinase 25,000 |
| Sponsor | Universitair Ziekenhuis Brussel |
| Drug class | Antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Taurolidine has antimicrobial properties that help to reduce bacterial load, while urokinase has fibrinolytic properties that help to break down blood clots and promote wound healing. This combination makes taurolidine urokinase effective in treating infections and promoting wound healing.
Approved indications
- Treatment of catheter-related bloodstream infections
Common side effects
- Hypersensitivity reactions
Key clinical trials
- Prevention of Dialysis Catheter Malfunction With Prophylactic Use of a Taurolidine Containing Urokinase (PHASE3)
- Comparison of a TauroLock™ Based Regimen to 4% Citrate as Lock Solution in Tunneled Haemodialysis Catheters for the Prevention of Bacteraemia and Dysfunction (PHASE4)
- Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Taurolidine Urokinase CI brief — competitive landscape report
- Taurolidine Urokinase updates RSS · CI watch RSS
- Universitair Ziekenhuis Brussel portfolio CI